<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624295</url>
  </required_header>
  <id_info>
    <org_study_id>HITs</org_study_id>
    <nct_id>NCT04624295</nct_id>
  </id_info>
  <brief_title>Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)</brief_title>
  <official_title>Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis in China (HITs)：a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shaoxing People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jiaxing University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huizhou Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Jiaxing University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No.2 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lishui Country People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth Affiliated Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous study showed that the proportions of hemorrhagic Infarction after intravenous&#xD;
      thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of&#xD;
      them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after&#xD;
      acute ischemic stroke. Previous study have shown no significant relationship between&#xD;
      hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this&#xD;
      study, a randomized controlled trial will be conducted to explore the efficacy and safety of&#xD;
      early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with&#xD;
      intravenous thrombolysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with modified Rankin scale (mRS) ≤2</measure>
    <time_frame>90 days</time_frame>
    <description>The proportion of patients with modified Rankin scale (mRS) ≤2 at 90 days, on which scores range from 0 (no neurologic deficit) to 6 (death)].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhage volume enlargement after intravenous thrombolysis</measure>
    <time_frame>7 days</time_frame>
    <description>Hemorrhage volume enlargement after intravenous thrombolysis at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhage volume reduction after intravenous thrombolysis</measure>
    <time_frame>7 days</time_frame>
    <description>Hemorrhage volume reduction after intravenous thrombolysis at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the progress of National Institute of Health Stroke Scale (NIHSS) scores</measure>
    <time_frame>7 days</time_frame>
    <description>the progress of National Institute of Health Stroke Scale (NIHSS) scores at 7 days, on which scores range from 0 (no neurologic deficit) to 42 (severe)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enlarged infarct volume within 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Enlarged infarct volume within 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the distribution of modified Rankin scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>the distribution of modified Rankin scale (mRS) at 90 days, on which scores range from 0 (no neurologic deficit) to 6 (death)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of acute ischemic stroke</measure>
    <time_frame>90 days</time_frame>
    <description>Recurrence rate of acute ischemic stroke at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of cerebrovascular disease</measure>
    <time_frame>90 days</time_frame>
    <description>Recurrence rate of cerebrovascular disease at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of acute ischemic stroke</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrence rate of acute ischemic stroke at 1 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of cerebrovascular disease</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrence rate of cerebrovascular disease at 1 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Antiplatelet Therapy</condition>
  <condition>Hemorrhagic Infarction</condition>
  <arm_group>
    <arm_group_label>Early Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Early Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early aspirin Therapy</intervention_name>
    <description>Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.</description>
    <arm_group_label>Early Antiplatelet Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-Early aspirin Therapy</intervention_name>
    <description>Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.</description>
    <arm_group_label>Non-Early Antiplatelet Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic patients receiving intravenous thrombolysis within 4.5 hours upon&#xD;
             stroke onset&#xD;
&#xD;
          2. Be confirmed as Hemorrhagic Infarction at 24 to 36 hours after intravenous&#xD;
             thrombolysis by computerized tomography&#xD;
&#xD;
          3. The patient or family member signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Early use of anticoagulant drugs within 1 week after intravenous thrombolysis;&#xD;
&#xD;
          2. Tirofiban was used after receiving endovascular treatment;&#xD;
&#xD;
          3. Intraoperative stent placement after receiving endovascular treatment;&#xD;
&#xD;
          4. Subarachnoid hemorrhage or ventricular hemorrhage;&#xD;
&#xD;
          5. There are contraindications for aspirin use;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Lou, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Lou, PhD</last_name>
    <phone>+8657187784810</phone>
    <email>loumingxc@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the second affiliated hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Lou</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>intravenous thrombolysis</keyword>
  <keyword>Hemorrhagic Infarction</keyword>
  <keyword>antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

